Top-News
Biotechnologie USA

TransCode Therapeutics Inc Aktie

Aktie
WKN:  A40VJX ISIN:  US89357L4023 US-Symbol:  RNAZ
0,561 $
-0,003 $
-0,53%
0,4951 € 01.05.25
Depot/Watchlist
Aktienanzahl *
696,25 Tsd.
Marktkapitalisierung *
249,88 Tsd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 29.01.2025

TransCode Therapeutics Inc News

01.05.25 - PR Newswire
TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer
TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer PR Newswire
21.04.25 - PR Newswire
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting PR Newswire
27.03.25 - PR Newswire
TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138
TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138 PR Newswire
25.03.25 - PR Newswire
TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering PR Newswire
23.03.25 - PR Newswire
TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-​the-Market Under Nasdaq Rules PR Newswire
13.03.25 - PR Newswire
TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial
TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial PR Newswire
25.02.25 - PR Newswire
TransCode Therapeutics, Inc. Announces Results of Special Meeting
TransCode Therapeutics, Inc. Announces Results of Special Meeting PR Newswire
06.02.25 - PR Newswire
TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial PR Newswire
04.02.25 - PR Newswire
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting PR Newswire
14.01.25 - PR Newswire
TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial
TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial PR Newswire
07.01.25 - PR Newswire
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements PR Newswire
18.12.24 - PR Newswire
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial PR ...

Newssuche

Videos

newspaper
30.04.25 +3,37%
Technical Trading: Cotton Long Chance
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »